Nope, I was wrong. Forgot they confirmed no further trials needed in the annual report.
It was my thought though that that would be a catalyst for the sp, which has turned out to be wrong. Funny, with other companies issue clarity by the FDA has been reason for rerating (up or down).
Add to My Watchlist
What is My Watchlist?